CSBR (Champions Oncology, Inc.) Stock Analysis - AI Report
Champions Oncology, Inc. (CSBR) is a publicly traded Healthcare sector company. As of May 21, 2026, CSBR trades at $5.99 with a market cap of $84.29M and a P/E ratio of 17.65. CSBR moved +0.00% today. Year to date, CSBR is -9.16%; over the trailing twelve months it is +2.20%. Its 52-week range spans $3.75 to $11.99. Rallies surfaces CSBR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What is the AI research view on CSBR?
Rallies AI research for CSBR combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
Mendelson Daniel Newman bought 1.00K (~$6.50K) on Jan 12, 2024.
Mendelson Daniel Newman bought 2.00K (~$12.54K) on Jan 11, 2024.
Mendelson Daniel Newman bought 2.94K (~$18.58K) on Jan 10, 2024.
CSBR Analyst Consensus
CSBR analyst coverage data. Average price target: $0.00.
Common questions about CSBR
What is the AI research view on CSBR?
Rallies AI research for CSBR combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
What data powers the Rallies AI report for CSBR?
Rallies AI research for CSBR combines live market data, financials, news, analyst context, hedge fund ownership, politician disclosures, insider activity, and risk factors.
Is CSBR research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CSBR. It does not provide personalized investment advice.
